doc_id,title,published_date,publication_type,url,has_competitor_affiliation
PMID:41657209,Two-Year Real-World Effectiveness of Deucravacitinib in Psoriasis: The Analysis Stratified by Prior Apremilast or Biologic Therapy.,2026-02-09,Journal Article,https://pubmed.ncbi.nlm.nih.gov/41657209/,0
PMID:41642152,"INDIVIDUAL ARTICLE: Evidence-Based Synthesis of Deucravacitinib: Long Term Efficacy, Safety, and Practical Use in Moderate-to-Severe Psoriasis.",2026-02-01,Journal Article,https://pubmed.ncbi.nlm.nih.gov/41642152/,0
PMID:41642132,Dual IL-17A/F Blockade for Acrodermatitis Continua of Hallopeau: A Clinical Response to Bimekizumab.,2026-02-01,Journal Article,https://pubmed.ncbi.nlm.nih.gov/41642132/,0
PMID:40974167,Investigation of infection risk associated with Janus kinase inhibitors: a pharmacovigilance analysis using the Food and Drug Administration's Adverse Event Reporting System database.,2026-01-27,Journal Article,https://pubmed.ncbi.nlm.nih.gov/40974167/,0
PMID:41596733,Systemic Treatment Strategies for Patients with Psoriasis and Psoriatic Arthritis in the Setting of ANA Positivity or Lupus Spectrum Disease: A Comprehensive Systematic Review.,2026-01-22,Journal Article,https://pubmed.ncbi.nlm.nih.gov/41596733/,0
PMID:41577058,Reframing Psoriasis Therapy: TYK2 Inhibition and the Erosion of the Oral-Biologic Divide.,2026-01-21,Letter,https://pubmed.ncbi.nlm.nih.gov/41577058/,0
PMID:41648065,Emerging Targets in Psoriatic Arthritis: Dual IL-17A/F and Selective TYK2 Inhibition in a Clinical Perspective.,2026-01-08,Journal Article,https://pubmed.ncbi.nlm.nih.gov/41648065/,0
PMID:41489211,Two-Year Real-World Effectiveness of Deucravacitinib 6 mg in Psoriasis: A Single-Center Analysis Stratified by Body Mass Index or Age in a Japanese Cohort.,2026-01-05,Journal Article,https://pubmed.ncbi.nlm.nih.gov/41489211/,0
PMID:41489170,The Maintenance of Early Responses and Achievement of Delayed Responses to Deucravacitinib Treatment in Psoriais: A 104-Week Real-World Study in Japan.,2026-01-05,Journal Article,https://pubmed.ncbi.nlm.nih.gov/41489170/,0
PMID:40991399,TYK2 Promotes Immunosurveillance of Colorectal Cancer Liver Metastasis.,2026-01-02,Journal Article,https://pubmed.ncbi.nlm.nih.gov/40991399/,0
PMID:41531416,"S3 Guideline for the treatment of psoriasis vulgaris, adapted from EuroGuiDerm - part 1: Treatment recommendations and monitoring.",2026-01,Journal Article,https://pubmed.ncbi.nlm.nih.gov/41531416/,0
PMID:41502380,Relative Efficacy of Immunomodulatory Monotherapies for Psoriasis of the Scalp: A Network Meta-Analysis Study.,2026-01,Journal Article,https://pubmed.ncbi.nlm.nih.gov/41502380/,0
PMID:41502049,The Relative Effects of Monotherapies for Psoriatic Nails: A Network Meta-Analysis Study.,2026-01,Journal Article,https://pubmed.ncbi.nlm.nih.gov/41502049/,0
PMID:41630865,"Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe scalp psoriasis: Efficacy and safety results through week 16 in a phase 3b/4, multicenter, randomized, double-blinded, placebo-controlled trial (PSORIATYK SCALP).",2025-12-22,Journal Article,https://pubmed.ncbi.nlm.nih.gov/41630865/,0
PMID:41393061,Dramatic clearance of extensive psoriasis in a pediatric patient treated with upadacitinib: A case report.,2025-12-11,Case Reports,https://pubmed.ncbi.nlm.nih.gov/41393061/,0
PMID:41379522,Deucravacitinib could be an effective and safe choice in patients affected with psoriasis and atopic dermatitis (Psorema)?,2025-12-11,Journal Article,https://pubmed.ncbi.nlm.nih.gov/41379522/,0
PMID:41350512,Deucravacitinib in Plaque Psoriasis After Inadequate Response to Apremilast: Phase 3 POETYK Analysis.,2025-12-05,Journal Article,https://pubmed.ncbi.nlm.nih.gov/41350512/,0
PMID:41327887,Targeting the JAK/STAT pathway in palmoplantar pustulosis: a review.,2025-12-01,Journal Article,https://pubmed.ncbi.nlm.nih.gov/41327887/,0
PMID:40972666,TYK-ed off by rosacea: an Australian case series of rosacea associated with deucravacitinib.,2025-11-25,Journal Article,https://pubmed.ncbi.nlm.nih.gov/40972666/,0
PMID:41261382,"Deucravacitinib in Psoriasis: Evidence, Gaps, and Place in Therapy.",2025-11-19,Journal Article,https://pubmed.ncbi.nlm.nih.gov/41261382/,0
PMID:41161603,"Response to Papp et al, ""Efficacy and safety of ESK-001, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: 52-week results from the long-term phase 2 study in patients who participated in the phase 2 STRIDE study"".",2025-10-27,Editorial,https://pubmed.ncbi.nlm.nih.gov/41161603/,0
PMID:41552704,Deucravacitinib for the treatment of moderate-to-severe palmoplantar pustulosis: Results from an early-terminated open-label trial.,2025-10-09,Journal Article,https://pubmed.ncbi.nlm.nih.gov/41552704/,0
PMID:41112262,Comprehensive disproportionality analysis of individual case safety reports associated with Janus kinase inhibitors in psoriasis and psoriatic arthritis using the FAERS database.,2025-10-02,Journal Article,https://pubmed.ncbi.nlm.nih.gov/41112262/,0
PMID:41029430,Cost-effectiveness of deucravacitinib versus apremilast of moderate-to-severe plaque psoriasis in China.,2025-09-30,Journal Article,https://pubmed.ncbi.nlm.nih.gov/41029430/,0
PMID:41096715,Review of Promising Off-Label Use of Deucravacitinib.,2025-09-27,Journal Article,https://pubmed.ncbi.nlm.nih.gov/41096715/,0
PMID:41025299,[A real world study on the effectiveness and safety of deu-cravacitinib in the treatment of moderate-to-severe plaque psoriasis in China].,2025-09-25,English Abstract,https://pubmed.ncbi.nlm.nih.gov/41025299/,0
PMID:40411449,Outcomes of Psoriasis Area and Severity Index (PASI) and PASI components in two phase III trials of deucravacitinib in patients with moderate to severe plaque psoriasis.,2025-09-25,Journal Article,https://pubmed.ncbi.nlm.nih.gov/40411449/,0
PMID:40976249,"Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials.",2025-09-18,Journal Article,https://pubmed.ncbi.nlm.nih.gov/40976249/,0
PMID:40920289,"Design of Two Randomized, Placebo-Controlled, Phase 3 Trials of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Systemic Lupus Erythematosus.",2025-09-08,Journal Article,https://pubmed.ncbi.nlm.nih.gov/40920289/,0
PMID:40695726,A Validated Quantitative LC-MS/MS Method for Determination of Deucravacitinib in Rat Plasma and Its Application to a Pharmacokinetic Study.,2025-09,Journal Article,https://pubmed.ncbi.nlm.nih.gov/40695726/,0
PMID:40856907,Management of Erythrodermic Psoriasis with Systemic Therapies: A Systematic Review.,2025-08-26,Journal Article,https://pubmed.ncbi.nlm.nih.gov/40856907/,0
PMID:40846809,A systematic review and network meta-analysis comparing the efficacy and safety of deucravacitinib versus selected treatments for moderate to severe plaque psoriasis.,2025-08-22,Comparative Study,https://pubmed.ncbi.nlm.nih.gov/40846809/,0
PMID:40836369,A Review of Phase III and Long-Term Data for Deucravacitinib for Plaque Psoriasis.,2025-08-20,Journal Article,https://pubmed.ncbi.nlm.nih.gov/40836369/,0
PMID:40823507,TYK2 rs34536443 (P1104A) Variant Suppresses ICAM1-Mediated Inflammation: Insights From Mendelian Randomization and Functional Analyses.,2025-08-12,Journal Article,https://pubmed.ncbi.nlm.nih.gov/40823507/,0
PMID:40782323,Safety evaluation of deucravacitinib: a real-world analysis based on the FDA adverse event reporting system database.,2025-08-09,Journal Article,https://pubmed.ncbi.nlm.nih.gov/40782323/,0
PMID:40767824,Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.,2025-08-06,Comparative Study,https://pubmed.ncbi.nlm.nih.gov/40767824/,0
PMID:41035834,"Effective management of psoriasis and psoriatic arthritis in a patient with systemic lupus erythematosus using deucravacitinib, mycophenolate mofetil and hydroxychloroquine.",2025-08-04,Case Reports,https://pubmed.ncbi.nlm.nih.gov/41035834/,0
PMID:40773611,Comparative Efficacy of Deucravacitinib and Adalimumab for Scalp Psoriasis: An Indirect Treatment Comparison.,2025-08-01,Journal Article,https://pubmed.ncbi.nlm.nih.gov/40773611/,0
PMID:40773602,Deucravacitinib With Add-On Calcipotriene/Betamethasone Dipropionate for Treating Moderate to Severe Plaque Psoriasis.,2025-08-01,Journal Article,https://pubmed.ncbi.nlm.nih.gov/40773602/,0
PMID:40742181,Conversion of Conjunctival Nevus to Melanoma in a Patient Taking the TYK2 Inhibitor Deucravacitinib.,2025-07-31,Journal Article,https://pubmed.ncbi.nlm.nih.gov/40742181/,0
PMID:40671612,"Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Asian Patients With Moderate to Severe Psoriasis: Improvements in Patient-Reported Outcomes in a Randomized Trial.",2025-07-17,Journal Article,https://pubmed.ncbi.nlm.nih.gov/40671612/,0
PMID:40655543,Deucravacitinib Improved Interstitial Pneumonia Along with KL-6 Reduction in a Patient with Psoriasis: A Case Report.,2025-07-08,Case Reports,https://pubmed.ncbi.nlm.nih.gov/40655543/,0
PMID:40616721,"Efficacy and Safety of Deucravacitinib, a Selective, Allosteric TYK2 Inhibitor, by Baseline DMARD Use in a Phase 2 Psoriatic Arthritis Study: A Post Hoc Analysis.",2025-07-05,Journal Article,https://pubmed.ncbi.nlm.nih.gov/40616721/,0
PMID:40557729,Deucravacitinib: Long-term safety and efficacy reaffirm its place in the psoriasis treatment landscape.,2025-07,Journal Article,https://pubmed.ncbi.nlm.nih.gov/40557729/,0
PMID:40571687,Psoriasis.,2025-06-26,Journal Article,https://pubmed.ncbi.nlm.nih.gov/40571687/,0
PMID:40468645,A cost-effectiveness analysis of deucravacitinib vs. apremilast in moderate-to-severe psoriasis patients in Japan.,2025-06-17,Journal Article,https://pubmed.ncbi.nlm.nih.gov/40468645/,0
PMID:40672022,Identifying Predictive Factors for Complete Skin Clearance at Week 52 by Deucravacitinib in Moderate-to-Severe Psoriasis: A Prospective Observational Study.,2025-06-15,Journal Article,https://pubmed.ncbi.nlm.nih.gov/40672022/,0
PMID:40490621,Deucravacitinib as a monotherapy for concurrent management of psoriasis and chronic spontaneous urticaria.,2025-06-09,Journal Article,https://pubmed.ncbi.nlm.nih.gov/40490621/,0
PMID:40476606,Successful Management of Multidrug-Resistant Psoriatic Arthritis Coexisting With Rheumatoid Arthritis Using a TYK2 Inhibitor Deucravacitinib-Based Regimen.,2025-06-06,Letter,https://pubmed.ncbi.nlm.nih.gov/40476606/,0
PMID:40355364,Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn's disease and ulcerative colitis.,2025-06-04,Journal Article,https://pubmed.ncbi.nlm.nih.gov/40355364/,0
PMID:40452604,The Sustainability of Week 16 Responses to Deucravacitinib Treatment for Patients With Psoriasis.,2025-06-02,Letter,https://pubmed.ncbi.nlm.nih.gov/40452604/,0
PMID:39786840,The effects of deucravacitinib on three cases of systemic sclerosis associated with psoriasis.,2025-06-01,Journal Article,https://pubmed.ncbi.nlm.nih.gov/39786840/,0
PMID:40568688,Male and female pattern hair loss.,2025-06,Journal Article,https://pubmed.ncbi.nlm.nih.gov/40568688/,0
PMID:40568686,Psoriasis: an update on topical and systemic therapies.,2025-06,Journal Article,https://pubmed.ncbi.nlm.nih.gov/40568686/,0
PMID:40445270,Deucravacitinib in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis: Improvements in Joint Pain and the Impact of Musculoskeletal Symptoms.,2025-05-30,Journal Article,https://pubmed.ncbi.nlm.nih.gov/40445270/,0
PMID:40439875,"Systematic review of comparative studies on emerging psoriasis treatments: comparing biologics with biologics, small molecule inhibitors with small molecule inhibitors, and biologics with small molecule inhibitors.",2025-05-29,Journal Article,https://pubmed.ncbi.nlm.nih.gov/40439875/,0
PMID:39774654,Efficacy of deucravacitinib and guselkumab in a patient with psoriasis who had experienced multiple failures of biologics: a case report.,2025-05-23,Journal Article,https://pubmed.ncbi.nlm.nih.gov/39774654/,0
PMID:40475785,Case Report: Effectiveness of deucravacitinib in chronic recurrent multifocal osteomyelitis and concomitant psoriasis.,2025-05-22,Case Reports,https://pubmed.ncbi.nlm.nih.gov/40475785/,0
PMID:40519492,Deucravacitinib Treatment for Psoriasis Complicated by Myelodysplastic Syndrome Without Exacerbation of the Underlying Hematologic Disorder: A Case Report.,2025-05-14,Case Reports,https://pubmed.ncbi.nlm.nih.gov/40519492/,0
PMID:40378946,A Triple-Action Inhibitory Mechanism of Allosteric TYK2-Specific Inhibitors.,2025-05-14,Journal Article,https://pubmed.ncbi.nlm.nih.gov/40378946/,0
PMID:40351849,Adverse Events Associated with Apremilast and Deucravacitinib for Psoriasis: A Pharmacovigilance Study Based on the FAERS Database.,2025-05-05,Journal Article,https://pubmed.ncbi.nlm.nih.gov/40351849/,0
PMID:39423145,"Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial.",2025-05-01,Journal Article,https://pubmed.ncbi.nlm.nih.gov/39423145/,0
PMID:40304108,"Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Japanese Patients With Plaque Psoriasis: In-Depth Analysis of Efficacy and Safety in the Phase 3 POETYK PSO-4 Trial.",2025-04-30,Journal Article,https://pubmed.ncbi.nlm.nih.gov/40304108/,0
PMID:39657275,"Long-term effectiveness and safety of deucravacitinib for psoriasis: a 52-week real-world study of genital, scalp and nail lesions.",2025-04-24,Journal Article,https://pubmed.ncbi.nlm.nih.gov/39657275/,0
PMID:40252783,Properties of FDA-approved small molecule protein kinase inhibitors: A 2025 update.,2025-04-17,Journal Article,https://pubmed.ncbi.nlm.nih.gov/40252783/,0
PMID:40237138,Rapid Clinical Improvement With Tyrosine Kinase 2 Inhibitor Deucravacitinib in Overlapping Psoriasis and Atopic Dermatitis.,2025-04-16,Journal Article,https://pubmed.ncbi.nlm.nih.gov/40237138/,0
PMID:40202574,Real-world safety of deucravacitinib: insights from the Food and Drug Administration Adverse Event Reporting System.,2025-04-09,Journal Article,https://pubmed.ncbi.nlm.nih.gov/40202574/,0
PMID:40200906,Computational insights of deucravacitinib's selectivity for TYK2 pseudokinase vs. JAK kinase domain via molecular modeling studies.,2025-04-09,Journal Article,https://pubmed.ncbi.nlm.nih.gov/40200906/,0
PMID:40210114,"ART26.12, an FABP5 Inhibitor, Shows Efficacy in Preclinical Psoriasis Models.",2025-04-08,Journal Article,https://pubmed.ncbi.nlm.nih.gov/40210114/,0
PMID:40177824,Successful treatment of subacute cutaneous lupus erythematosus with the TYK-2 inhibitor deucravacitinib in a patient with concomitant psoriasis vulgaris.,2025-04-03,Letter,https://pubmed.ncbi.nlm.nih.gov/40177824/,0
PMID:40048065,Correction to: Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials.,2025-04,Published Erratum,https://pubmed.ncbi.nlm.nih.gov/40048065/,0
PMID:40176687,Pharmacological Management of Psoriasis: Current Landscape and Future Perspectives.,2025-03-28,Journal Article,https://pubmed.ncbi.nlm.nih.gov/40176687/,0
PMID:40113724,Deucravacitinib: Laboratory Parameters Across Phase 3 Plaque Psoriasis Trials.,2025-03-20,Journal Article,https://pubmed.ncbi.nlm.nih.gov/40113724/,0
PMID:40066907,"Deucravacitinib in plaque psoriasis: Safety and efficacy through 3 years in Japanese patients in the phase 3 POETYK PSO-1, PSO-4, and LTE trials.",2025-03-11,Journal Article,https://pubmed.ncbi.nlm.nih.gov/40066907/,0
PMID:40045918,"Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials.",2025-03-06,Journal Article,https://pubmed.ncbi.nlm.nih.gov/40045918/,0
PMID:40095888,The Expanding Therapeutic Potential of Deucravacitinib Beyond Psoriasis: A Narrative Review.,2025-03-05,Journal Article,https://pubmed.ncbi.nlm.nih.gov/40095888/,0
PMID:40095854,"Exploring the Efficacy, Safety, and Clinical Implications of Deucravacitinib in East Asians with Psoriasis: A Narrative Review.",2025-03-05,Journal Article,https://pubmed.ncbi.nlm.nih.gov/40095854/,0
PMID:40029105,A Physiologically Based Pharmacokinetic Model of an Oral Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Adults.,2025-03-03,Journal Article,https://pubmed.ncbi.nlm.nih.gov/40029105/,0
PMID:40038877,Topical TYK2 inhibitor ameliorates psoriasis-like dermatitis via the AKT-SP1-NGFR-AP1 pathway in keratinocytes.,2025-03,Journal Article,https://pubmed.ncbi.nlm.nih.gov/40038877/,0
PMID:39437312,"Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan and South Korea with moderate-to-severe plaque psoriasis: a phase III randomized clinical trial.",2025-02-18,Journal Article,https://pubmed.ncbi.nlm.nih.gov/39437312/,0
PMID:40109802,Therapeutic Advancements in the Management of Psoriasis: A Clinical Overview and Update.,2025-02-16,Journal Article,https://pubmed.ncbi.nlm.nih.gov/40109802/,0
PMID:39918727,Deucravacitinib: Adverse Events of Interest Across Phase 3 Plaque Psoriasis Trials.,2025-02-07,Journal Article,https://pubmed.ncbi.nlm.nih.gov/39918727/,0
PMID:39916637,Long-term real-world effectiveness of deucravacitinib in psoriasis: A 52-week prospective study stratified by prior apremilast or biologic therapy.,2025-02-07,Journal Article,https://pubmed.ncbi.nlm.nih.gov/39916637/,0
PMID:39913225,A Review of the Safety and Efficacy of Deucravacitinib for Plaque Psoriasis: An Expert Consensus Panel.,2025-02-01,Journal Article,https://pubmed.ncbi.nlm.nih.gov/39913225/,0
PMID:39891469,Acneiform Eruption Secondary to Deucravacitinib: A Case Series and Review of the Literature.,2025-02-01,Journal Article,https://pubmed.ncbi.nlm.nih.gov/39891469/,0
PMID:40078858,From the Masterclasses in Dermatology 2024 Meeting: Updates in Psoriasis Treatments.,2025-02,Journal Article,https://pubmed.ncbi.nlm.nih.gov/40078858/,0
PMID:39873274,Real-world 52-week effectiveness of deucravacitinib in psoriasis: A stratified analysis by age and body mass index.,2025-01-28,Journal Article,https://pubmed.ncbi.nlm.nih.gov/39873274/,0
PMID:39602111,Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years: An Open-Label Extension of Randomized Clinical Trials.,2025-01-01,Journal Article,https://pubmed.ncbi.nlm.nih.gov/39602111/,0
PMID:40696716,Synthesis of Radiolabeled and Stable-Isotope Labeled Deucravacitinib (BMS-986165).,2025,Journal Article,https://pubmed.ncbi.nlm.nih.gov/40696716/,0
PMID:39723549,Predictive factors for responders to deucravacitinib treatment in patients with psoriasis.,2024-12-26,Journal Article,https://pubmed.ncbi.nlm.nih.gov/39723549/,0
PMID:39096269,"Effectiveness of deucravacitinib for genital, nail and scalp lesions in patients with psoriasis: a 24-week real-world study.",2024-12-23,Journal Article,https://pubmed.ncbi.nlm.nih.gov/39096269/,0
PMID:39698762,A case of Bell palsy during the course of oral TYK2 inhibitor deucravacitinib therapy in psoriasis.,2024-12-19,Letter,https://pubmed.ncbi.nlm.nih.gov/39698762/,0
PMID:39830543,Green Nail in a Patient With Psoriasis Receiving Deucravacitinib.,2024-12-17,Case Reports,https://pubmed.ncbi.nlm.nih.gov/39830543/,0
PMID:39684939,"Characterising a Novel Therapeutic Target for Psoriasis, TYK2, Using Functional Genomics.",2024-12-09,Journal Article,https://pubmed.ncbi.nlm.nih.gov/39684939/,0
PMID:39641509,"Deucravacitinib in Japanese patients with plaque, generalized pustular, or erythrodermic psoriasis: Patient-reported outcomes in the POETYK PSO-4 study.",2024-12-06,Journal Article,https://pubmed.ncbi.nlm.nih.gov/39641509/,0
PMID:39641243,A systematic review of the efficacy of TYK2 inhibitors in patients with dermatological disease.,2024-12-06,Journal Article,https://pubmed.ncbi.nlm.nih.gov/39641243/,0
PMID:39632465,Hair regrowth in a patient with alopecia universalis and psoriasis vulgaris during deucravacitinib therapy.,2024-12-04,Case Reports,https://pubmed.ncbi.nlm.nih.gov/39632465/,0
PMID:39879362,Successful Treatment of Severe Dystrophic Nail Psoriasis With Deucravacitinib.,2024-12,Letter,https://pubmed.ncbi.nlm.nih.gov/39879362/,0
PMID:39777044,Deucravacitinib for plaque psoriasis.,2024-12,Journal Article,https://pubmed.ncbi.nlm.nih.gov/39777044/,0
PMID:39526612,Indirect comparison of deucravacitinib and other systemic treatments for moderate to severe plaque psoriasis in Asian populations: A systematic literature review and network meta-analysis.,2024-11-11,Comparative Study,https://pubmed.ncbi.nlm.nih.gov/39526612/,0
PMID:38607726,Reappraising the Use of Systemic Immunomodulators for Psoriasis and Eczema in the Military.,2024-11-05,Journal Article,https://pubmed.ncbi.nlm.nih.gov/38607726/,0
PMID:39473371,Dual-Action Psoriasis Therapy: Antiproliferative and Immunomodulatory Effects via Self-Locking Microneedles.,2024-10-30,Journal Article,https://pubmed.ncbi.nlm.nih.gov/39473371/,0
PMID:39453596,Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis.,2024-10-25,Journal Article,https://pubmed.ncbi.nlm.nih.gov/39453596/,0
PMID:39395444,Response to deucravacitinib in psoriasis patients with prior biologic therapy failures: A retrospective study.,2024-10-11,Journal Article,https://pubmed.ncbi.nlm.nih.gov/39395444/,0
PMID:39463216,"The Pathophysiology, Diagnosis and Management of Chronic Inflammatory Skin Diseases.",2024-10,Journal Article,https://pubmed.ncbi.nlm.nih.gov/39463216/,0
PMID:39302349,Comparison table: Some drugs for plaque psoriasis.,2024-09-30,Journal Article,https://pubmed.ncbi.nlm.nih.gov/39302349/,0
PMID:39302348,Drugs for plaque psoriasis.,2024-09-30,Journal Article,https://pubmed.ncbi.nlm.nih.gov/39302348/,0
PMID:39349269,Tyrosine kinase 2 inhibitors in autoimmune diseases.,2024-09-29,Journal Article,https://pubmed.ncbi.nlm.nih.gov/39349269/,0
PMID:39353258,The multiple-action allosteric inhibition of TYK2 by deucravacitinib: Insights from computational simulations.,2024-09-27,Journal Article,https://pubmed.ncbi.nlm.nih.gov/39353258/,0
PMID:39507477,Mycosis fungoides with large cell transformation associated with oral deucravacitinib.,2024-09-24,Case Reports,https://pubmed.ncbi.nlm.nih.gov/39507477/,0
PMID:39283417,"Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial.",2024-09-16,Journal Article,https://pubmed.ncbi.nlm.nih.gov/39283417/,0
PMID:39542556,Innovations in Psoriasis.,2024-09-10,Journal Article,https://pubmed.ncbi.nlm.nih.gov/39542556/,0
PMID:39255968,Exploring the effect of deucravacitinib in patients with palmoplantar pustular psoriasis.,2024-09-10,Journal Article,https://pubmed.ncbi.nlm.nih.gov/39255968/,0
PMID:39131603,New and emerging oral therapies for psoriasis.,2024-08-01,Journal Article,https://pubmed.ncbi.nlm.nih.gov/39131603/,0
PMID:39093663,Selective Tyrosine Kinase 2 (TYK2) Inhibition in Plaque Psoriasis.,2024-08-01,Journal Article,https://pubmed.ncbi.nlm.nih.gov/39093663/,0
PMID:39180322,Safety and efficacy of Deucravacitinib for moderate to severe plaque psoriasis: A meta-analysis.,2024-08,Journal Article,https://pubmed.ncbi.nlm.nih.gov/39180322/,0
PMID:39084258,Augmentative effects of leukemia inhibitory factor reveal a critical role for TYK2 signaling in vascular calcification.,2024-07-30,Journal Article,https://pubmed.ncbi.nlm.nih.gov/39084258/,0
PMID:39080153,Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials.,2024-07-30,Journal Article,https://pubmed.ncbi.nlm.nih.gov/39080153/,0
PMID:39201826,"Biologics and Small Molecule Targeted Therapies for Pediatric Alopecia Areata, Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa in the US: A Narrative Review.",2024-07-25,Journal Article,https://pubmed.ncbi.nlm.nih.gov/39201826/,0
PMID:39149635,Paradoxical Eczema Associated With Interleukin-17A Inhibitor Use in a Patient With Generalized Pustular Psoriasis Accompanied by Asthma.,2024-07-16,Case Reports,https://pubmed.ncbi.nlm.nih.gov/39149635/,0
PMID:38976593,Deucravacitinib: moderate-to-severe plaque psoriasis preventable?,2024-07-09,Journal Article,https://pubmed.ncbi.nlm.nih.gov/38976593/,0
PMID:38770592,"Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses.",2024-07-01,Journal Article,https://pubmed.ncbi.nlm.nih.gov/38770592/,0
PMID:38945549,Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials.,2024-06-30,Journal Article,https://pubmed.ncbi.nlm.nih.gov/38945549/,0
PMID:38914425,Cost per response analysis of deucravacitinib versus apremilast and first-line biologics among patients with moderate to severe plaque psoriasis in the United States.,2024-06-24,Journal Article,https://pubmed.ncbi.nlm.nih.gov/38914425/,0
PMID:38907877,Cumulative Benefit Over 52 Weeks With Deucravacitinib Versus Apremilast in Moderate to Severe Plaque Psoriasis: POETYK PSO-1 Post Hoc Analysis.,2024-06-22,Journal Article,https://pubmed.ncbi.nlm.nih.gov/38907877/,0
PMID:38895380,TYK2 as a novel therapeutic target in Alzheimer's Disease with TDP-43 inclusions.,2024-06-06,Journal Article,https://pubmed.ncbi.nlm.nih.gov/38895380/,0
PMID:38892802,Therapeutic Potential of Targeting the JAK/STAT Pathway in Psoriasis: Focus on TYK2 Inhibition.,2024-05-24,Journal Article,https://pubmed.ncbi.nlm.nih.gov/38892802/,0
PMID:38503473,Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis.,2024-05-15,Journal Article,https://pubmed.ncbi.nlm.nih.gov/38503473/,0
PMID:38799436,Reactive oxygen species-responsive supramolecular deucravacitinib self-assembly polymer micelles alleviate psoriatic skin inflammation by reducing mitochondrial oxidative stress.,2024-05-10,Journal Article,https://pubmed.ncbi.nlm.nih.gov/38799436/,0
PMID:38529674,Improvements in Patient-Reported Outcomes After Treatment With Deucravacitinib in Patients With Psoriatic Arthritis: Results From a Randomized Phase 2 Trial.,2024-05-07,Journal Article,https://pubmed.ncbi.nlm.nih.gov/38529674/,0
PMID:38709397,Management of Psoriasis Patients with Serious Infectious Diseases.,2024-05-06,Journal Article,https://pubmed.ncbi.nlm.nih.gov/38709397/,0
PMID:38699874,Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluation.,2024-05-06,Journal Article,https://pubmed.ncbi.nlm.nih.gov/38699874/,0
PMID:38731900,Inhibition of the JAK-STAT Pathway in the Treatment of Psoriasis: A Review of the Literature.,2024-04-25,Journal Article,https://pubmed.ncbi.nlm.nih.gov/38731900/,0
PMID:38407434,Deucravacitinib: is there still a place or a need for a new oral agent?,2024-04-17,Editorial,https://pubmed.ncbi.nlm.nih.gov/38407434/,0
PMID:38226713,Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials.,2024-04-17,Randomized Controlled Trial,https://pubmed.ncbi.nlm.nih.gov/38226713/,0
PMID:38796267,Oral Psoriasis Therapies.,2024-04-04,Journal Article,https://pubmed.ncbi.nlm.nih.gov/38796267/,0
PMID:38529623,Clinical pharmacokinetics and pharmacodynamics of oral systemic nonbiologic therapies for psoriasis patients.,2024-03-28,Journal Article,https://pubmed.ncbi.nlm.nih.gov/38529623/,0
PMID:38499181,Full Guidelines-From the Medical Board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis.,2024-03-17,Journal Article,https://pubmed.ncbi.nlm.nih.gov/38499181/,0
PMID:38467779,TYK2: an emerging therapeutic target in rheumatic disease.,2024-03-11,Journal Article,https://pubmed.ncbi.nlm.nih.gov/38467779/,0
PMID:38451052,Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2).,2024-03-07,Journal Article,https://pubmed.ncbi.nlm.nih.gov/38451052/,0
PMID:38443116,First Use of Combination Oral Deucravacitinib With Tapinarof Cream for Treatment of Severe Plaque Psoriasis.,2024-03-01,Case Reports,https://pubmed.ncbi.nlm.nih.gov/38443116/,0
PMID:38444845,Application of JAK inhibitors in paradoxical reaction through immune-related dermatoses.,2024-02-20,Journal Article,https://pubmed.ncbi.nlm.nih.gov/38444845/,0
PMID:38331098,Vaccination recommendations for adults receiving biologics and oral therapies for psoriasis and psoriatic arthritis: Delphi consensus from the medical board of the National Psoriasis Foundation.,2024-02-07,Journal Article,https://pubmed.ncbi.nlm.nih.gov/38331098/,0
PMID:38399292,New and Emerging Oral/Topical Small-Molecule Treatments for Psoriasis.,2024-02-06,Journal Article,https://pubmed.ncbi.nlm.nih.gov/38399292/,0
PMID:38305215,Effectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in Japan.,2024-02-02,Journal Article,https://pubmed.ncbi.nlm.nih.gov/38305215/,0
PMID:38306122,Deucravacitinib for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.,2024-02-01,Meta-Analysis,https://pubmed.ncbi.nlm.nih.gov/38306122/,0
PMID:38117487,Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary: A Secondary Analysis of a Randomized Clinical Trial.,2024-02-01,Randomized Controlled Trial,https://pubmed.ncbi.nlm.nih.gov/38117487/,0
PMID:38280146,Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Moderate-to-Severe Psoriasis.,2024-01-27,Journal Article,https://pubmed.ncbi.nlm.nih.gov/38280146/,0
PMID:38268101,"Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: Efficacy and safety results from an open-label, phase 3 trial.",2024-01-24,"Clinical Trial, Phase III",https://pubmed.ncbi.nlm.nih.gov/38268101/,0
PMID:37997745,Efficacy of tyrosine-kinase-2 and phosphodiesterase-4 inhibitors for scalp psoriasis: a systematic review and meta-analysis.,2024-01-24,Meta-Analysis,https://pubmed.ncbi.nlm.nih.gov/37997745/,0
PMID:38212257,Bimekizumab (Bimzelx) for psoriasis.,2024-01-22,Journal Article,https://pubmed.ncbi.nlm.nih.gov/38212257/,0
PMID:38216005,Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update.,2024-01-11,Journal Article,https://pubmed.ncbi.nlm.nih.gov/38216005/,0
PMID:38904160,Targeting TYK2 for Fighting Diseases: Recent Advance of TYK2 Inhibitors.,2024,Journal Article,https://pubmed.ncbi.nlm.nih.gov/38904160/,0
PMID:38899421,Comparative efficacy and safety of JAK/TYK2 inhibitors and other oral drugs for moderate-to-severe plaque psoriasis: Systematic review and network meta-analysis.,2024,Journal Article,https://pubmed.ncbi.nlm.nih.gov/38899421/,0
PMID:38876119,Deucravacitinib and shikonin combination therapy ameliorates imiquimod-induced psoriasis in mice.,2024,Journal Article,https://pubmed.ncbi.nlm.nih.gov/38876119/,0
PMID:38122848,"Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis.",2023-12-18,"Clinical Trial, Phase III",https://pubmed.ncbi.nlm.nih.gov/38122848/,0
PMID:38169994,Bibliometric analysis and description of research trends on T cells in psoriasis over the past two decades (2003-2022).,2023-12-10,Journal Article,https://pubmed.ncbi.nlm.nih.gov/38169994/,0
PMID:38033914,Rapid hair regrowth in an alopecia universalis patient with deucravacitinib: A case report.,2023-11-29,Case Reports,https://pubmed.ncbi.nlm.nih.gov/38033914/,0
PMID:38007038,Nail psoriasis and nail lichen planus: Updates on diagnosis and management.,2023-11-24,Journal Article,https://pubmed.ncbi.nlm.nih.gov/38007038/,0
PMID:37981596,Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects.,2023-11-19,Journal Article,https://pubmed.ncbi.nlm.nih.gov/37981596/,0
PMID:38098574,A paradigm shift in psoriasis treatment: deucravacitinib's significance.,2023-11-07,Editorial,https://pubmed.ncbi.nlm.nih.gov/38098574/,0
PMID:37853229,Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis.,2023-11,Published Erratum,https://pubmed.ncbi.nlm.nih.gov/37853229/,0
PMID:37927384,JAK Inhibitors in Psoriatic Disease.,2023-10-31,Journal Article,https://pubmed.ncbi.nlm.nih.gov/37927384/,0
PMID:37901688,Comparative short-term risks of infection and serious infection in patients receiving biologic and small-molecule therapies for psoriasis and psoriatic arthritis: a systemic review and network meta-analysis of randomized controlled trials.,2023-10-27,Journal Article,https://pubmed.ncbi.nlm.nih.gov/37901688/,0
PMID:37863021,Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitors.,2023-10-18,Journal Article,https://pubmed.ncbi.nlm.nih.gov/37863021/,0
PMID:37845748,A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways.,2023-10-16,Video-Audio Media,https://pubmed.ncbi.nlm.nih.gov/37845748/,0
PMID:37873392,Triple-action inhibitory mechanism of allosteric TYK2-specific inhibitors.,2023-10-09,Journal Article,https://pubmed.ncbi.nlm.nih.gov/37873392/,0
PMID:37801281,"Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis.",2023-10-06,Journal Article,https://pubmed.ncbi.nlm.nih.gov/37801281/,0
PMID:37841017,The efficacy and safety of tyrosine kinase 2 inhibitor deucravacitinib in the treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.,2023-09-29,Systematic Review,https://pubmed.ncbi.nlm.nih.gov/37841017/,0
PMID:38188537,Deucravacitinib: a novel TYK2 inhibitor for the treatment of moderate-to-severe psoriasis.,2023-09-05,Journal Article,https://pubmed.ncbi.nlm.nih.gov/38188537/,0
PMID:37653331,[Not Available].,2023-09,Journal Article,https://pubmed.ncbi.nlm.nih.gov/37653331/,0
PMID:37634105,SOTYKTUTM (Deucravacitinib 6-mg Tablets)- A New Agent for the Management of Adult Plaque Psoriasis.,2023-08-28,Journal Article,https://pubmed.ncbi.nlm.nih.gov/37634105/,0
PMID:37578217,Progress on the Pharmacological Targeting of Janus Pseudokinases.,2023-08-14,Journal Article,https://pubmed.ncbi.nlm.nih.gov/37578217/,0
PMID:37574849,The preclinical discovery and development of deucravacitinib for the treatment of psoriasis.,2023-08-13,Review,https://pubmed.ncbi.nlm.nih.gov/37574849/,0
PMID:37507233,Psoriasis: a focus on upcoming oral formulations.,2023-08-01,Journal Article,https://pubmed.ncbi.nlm.nih.gov/37507233/,0
PMID:37525000,Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis.,2023-07-31,Journal Article,https://pubmed.ncbi.nlm.nih.gov/37525000/,0
PMID:37513344,Fast and Sensitive Bioanalytical Method for the Determination of Deucravacitinib in Human Plasma Using HPLC-MS/MS: Application and Greenness Evaluation.,2023-07-17,Journal Article,https://pubmed.ncbi.nlm.nih.gov/37513344/,0
PMID:37436070,Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.,2023-07-12,Journal Article,https://pubmed.ncbi.nlm.nih.gov/37436070/,0
PMID:37341177,Deucravacitinib: The First FDA-Approved Oral TYK2 Inhibitor for Moderate to Severe Plaque Psoriasis.,2023-06-21,Journal Article,https://pubmed.ncbi.nlm.nih.gov/37341177/,0
PMID:37287330,TYK2 as a novel therapeutic target in psoriasis.,2023-06-07,Journal Article,https://pubmed.ncbi.nlm.nih.gov/37287330/,0
PMID:37334353,Oral small-molecule tyrosine kinase 2 and phosphodiesterase 4 inhibitors in plaque psoriasis: a network meta-analysis.,2023-06-02,Journal Article,https://pubmed.ncbi.nlm.nih.gov/37334353/,0
PMID:37223005,Clinical Utility of Deucravacitinib for the Management of Moderate to Severe Plaque Psoriasis.,2023-05-18,Journal Article,https://pubmed.ncbi.nlm.nih.gov/37223005/,0
PMID:37147879,"Deucravacitinib, a selective tyrosine kinase 2 inhibitor, for the treatment of moderate-to-severe plaque psoriasis.",2023-05-09,Journal Article,https://pubmed.ncbi.nlm.nih.gov/37147879/,0
PMID:37150956,Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summary.,2023-05-07,Journal Article,https://pubmed.ncbi.nlm.nih.gov/37150956/,0
PMID:37150952,Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-1 study): a plain language summary.,2023-05-07,Journal Article,https://pubmed.ncbi.nlm.nih.gov/37150952/,0
PMID:37168605,Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature.,2023-05-04,Journal Article,https://pubmed.ncbi.nlm.nih.gov/37168605/,0
PMID:37168876,Deucravacitinib for the treatment of psoriatic arthritis: the evidence so far.,2023-05-03,Journal Article,https://pubmed.ncbi.nlm.nih.gov/37168876/,0
PMID:37096862,Recent developments for new investigational JAK inhibitors in psoriatic arthritis.,2023-05-03,Review,https://pubmed.ncbi.nlm.nih.gov/37096862/,0
PMID:37083505,New synthetic pharmacotherapeutic approaches to the treatment of moderate-to-severe plaque psoriasis in adults.,2023-04-27,Review,https://pubmed.ncbi.nlm.nih.gov/37083505/,0
PMID:37132187,English version of Japanese guidance for the use of oral Janus kinase inhibitors (JAK1 and TYK2 inhibitors) in the treatments of psoriasis.,2023-04-01,Journal Article,https://pubmed.ncbi.nlm.nih.gov/37132187/,0
PMID:36882942,"Efficacy and safety of the selective TYK2 inhibitor, deucravacitinib, in Japanese patients with moderate to severe plaque psoriasis: Subgroup analysis of a randomized, double-blind, placebo-controlled, global phase 3 trial.",2023-03-07,"Clinical Trial, Phase III",https://pubmed.ncbi.nlm.nih.gov/36882942/,0
PMID:36841716,Deucravacitinib (Sotyktuâ„¢) for plaque psoriasis.,2023-02-23,Journal Article,https://pubmed.ncbi.nlm.nih.gov/36841716/,0
PMID:36834806,Tyk2 Targeting in Immune-Mediated Inflammatory Diseases.,2023-02-08,Journal Article,https://pubmed.ncbi.nlm.nih.gov/36834806/,0
PMID:37075192,New Treatments for Psoriasis: An Update on a Therapeutic Frontier.,2023-02,Journal Article,https://pubmed.ncbi.nlm.nih.gov/37075192/,0
PMID:38031699,"Janus-kinase inhibitors in dermatology: A review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease.",2023,Journal Article,https://pubmed.ncbi.nlm.nih.gov/38031699/,0
